Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20

Core Insights - ONWARD Medical N.V. is a leading neurotechnology company focused on therapies for spinal cord injuries and movement disabilities, with a recent Buy rating initiated by BNP Paribas' broker Portzamparc and a target price of EUR 10.20 [1][2] Company Overview - ONWARD Medical is pioneering therapies to restore movement and independence in individuals with spinal cord injuries, having developed ARC Therapy and received 10 Breakthrough Device designations from the FDA [3] - The ARC-EX® System is now cleared for commercial sale in both the U.S. and Europe, marking a significant transition to a commercial-stage company [2][3] - The company is also advancing the investigational ARC-IM® platform, which aims to address unmet needs such as blood pressure instability post-injury and can integrate with brain-computer interfaces and AI for thought-driven movement [3] Market Position - The initiation of coverage by Portzamparc expands ONWARD's equity research coverage to five banks, all maintaining a Buy rating and target prices significantly above current trading levels, indicating strong analyst confidence in the company's growth prospects [2]